logo

Clinical Trial Results

Share

British drug major AstraZeneca (AZN.L, AZN) announced Thursday that new analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirmed robust efficacy and long-term prevention. The company noted that new data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient...

GlaxoSmithKline PLC (GSK.L, GSK) and Vir Biotechnology, Inc. (VIR) reported headline data from the randomised, open-label COMET-TAIL phase III trial, which achieved its primary endpoint. The data showed that intramuscular administration of sotrovimab was non-inferior to intravenous administration for...

Moderna Inc. (MRNA) has submitted for a variation to the conditional marketing authorization with the European Medicines Agency for the evaluation of a 50 g two-dose series of mRNA-12731 in children ages 6-11 years. The company noted that this marks its first submission for the use of vaccine in this...

Pfizer Inc. (PFE) said its investigational COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization and death, based on an interim analysis of the phase 2/3 EPIC-HR double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe...

Follow RTT